article thumbnail

STAT+: Drug may make chemotherapies less effective in cancer patients with obesity — but many doctors are in the dark

STAT

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. At issue is a medicine called posaconazole that was approved in 2006 in the U.S. And the company has refused to update the language. but is now also sold by generic companies.

article thumbnail

STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more

STAT

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. At issue is a medicine called posaconazole that was approved in 2006 in the U.S. At issue is a medicine called posaconazole that was approved in 2006 in the U.S.

Labelling 251
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

RFID: The future of smart labelling?

Pharmaceutical Technology

Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. What lies ahead for RFID and smart labelling Volpe says “the future is bright” for smart technologies that identify, monitor, and track medications through the supply chain.

Labelling 105
article thumbnail

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble? (rerun)

Drug Channels

During Friday's webinar, Ill share some updated thoughts on biosimilars and PBMs private label products. Below, we review the 20 products competing with Humiraincluding four private-label products marketed by in-house subsidiaries owned by CVS Health and Cigna. Click here to see the original post. All rights reserved.

article thumbnail

Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Drug Channels

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

article thumbnail

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Drug Channels

Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. There’s still time to request an invite to the inaugural Drug Channels Leadership Forum. Attendance will be highly limited. We have already begun extending invitations, so apply now to be considered. Click here to view the full agenda.

article thumbnail

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

Drug Channels

Below, we review the 18 products competing with Humira—including four private-label products marketed by in-house subsidiaries owned by CVS Health and Cigna. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.